Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 2971-2975

  Qiu, Jun Jun ^a   Guo, Jun Jie ^b   Lv, Tian Jiao ^a   Jin, Hong Yan ^a   Ding, Jing Xin ^a   Feng, Wei Wei ^a   Zhang, Ying ^a   Hua, Ke Qin ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Biomarker; CENP A; EOC; Prognosis

Indexed keywords

CENTROMERE PROTEIN A; MESSENGER RNA;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CENP A ONCOGENE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NONCANCER TISSUE; ONCOGENE; OVARIECTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

EID: 84885431018     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0860-6     Document Type: Article

References (13)

1. Tang L, Yang J, Ng SK, Rodriguez N, Choi PW, Vitonis A, et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer. 2010;46:170-9. doi: 10.1016/j.ejca.2009. 10.003.
2. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 2011;71:349-59. doi: 10.1158/0008-5472.CAN-10-2550.
3. Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010;16:5320-8. doi: 10.1158/1078-0432.CCR-10-0974.
4. Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, et al. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol. 2011;122:366-71. doi: 10.1016/j.ygyno.2011.04. 033.
5. Noske A, Kaszubiak A, Weichert W, Sers C, Niesporek S, Koch I, et al. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett. 2007;246:190-200. doi: 10.1016/j.canlet.2006.02.018.
6. Black BE, Jansen LE, Maddox PS, Foltz DR, Desai AB, Shah JV, et al. Centromere identity maintained by nucleosomes assembled with histone H3 containing the CENP-A targeting domain. Mol Cell. 2007;25:309-22. doi: 10.1016/j.molcel.2006.12.018.
7. Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, et al. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One. 2011;6:e17794. doi: 10.1371/journal.pone.0017794.
8. Tomonaga T, Matsushita K, Yamaguchi S, Oohashi T, Shimada H, Ochiai T, et al. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res. 2003;63:3511-6.
9. Wu Q, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, et al. Expression and prognostic significance of centromere protein A in human lung adenocarcinoma. Lung Cancer. 2012;77:407-14. doi: 10.1016/j.lungcan.2012.04.007.
10. McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012;14:R72. doi: 10.1186/bcr3181.
11. Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23:919-27. doi: 10.1007/s10552-012-9963-4.
12. Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, Islami F, et al. Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis. Gynecol Oncol. 2012;125:758-63. doi: 10.1016/j.ygyno.2012.03.031.
13. Wang M, He Y, Shi L, Shi C. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol. 2011;32:171-7.